Showing results (91-100 of 109) with videos related to
Sort By:
Pageof 11
Journal of Medicinal Chemistry|September 16, 2005
Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitorsYujia Dai, Yan Guo, Robin R Frey, et al.Epilepsia|September 9, 2005
Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activityWilliam J Giardina, Michael J Dart, Richard R Harris, et al.Bioorganic & Medicinal Chemistry Letters|March 14, 2007
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activityAndrew S Judd, Andrew J Souers, Dariusz Wodka, et al.Journal of Medicinal Chemistry|March 9, 2007
Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitorYujia Dai, Kresna Hartandi, Zhiqin Ji, et al.Bioorganic & Medicinal Chemistry Letters|September 22, 2010
Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivativesMichael E Kort, Robert N Atkinson, James B Thomas, et al.Journal of Medicinal Chemistry|January 11, 2008
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitorGang Zhao, Andrew J Souers, Martin Voorbach, et al.Bioorganic & Medicinal Chemistry|May 27, 2008
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic painIrene Drizin, Robert J Gregg, Marc J C Scanio, et al.Bioorganic & Medicinal Chemistry Letters|December 26, 2006
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylaminesAndrew J Souers, Rajesh R Iyengar, Andrew S Judd, et al.Journal of Medicinal Chemistry|October 27, 2006
Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safetyJohn K Lynch, Jennifer C Freeman, Andrew S Judd, et al.International Journal for Parasitology|April 1, 2020
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learnedRyan Choi, Matthew A Hulverson, Wenlin Huang, et al.Pageof 11